Log in

Relevant bibliographies by topics / Pharmacometrics

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Pharmacometrics'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 May 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmacometrics.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pharmacometrics"

1

Gobburu, Jogarao V. S. "Pharmacometrics 2020." Journal of Clinical Pharmacology 50, S9 (September 2010): 151S—157S. http://dx.doi.org/10.1177/0091270010376977.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Liu, Xiaoxi, and Robert M. Ward. "Pharmacometrics in Pediatrics." Therapeutic Innovation & Regulatory Science 53, no. 5 (September 2019): 579–83. http://dx.doi.org/10.1177/2168479019851793.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Mager, Donald E. "Future of Pharmacometrics." Proceedings for Annual Meeting of The Japanese Pharmacological Society WCP2018 (2018): CL—15. http://dx.doi.org/10.1254/jpssuppl.wcp2018.0_cl-15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Fukuda, Tsuyoshi. "Pharmacometrics in children." Proceedings for Annual Meeting of The Japanese Pharmacological Society WCP2018 (2018): SY35–2. http://dx.doi.org/10.1254/jpssuppl.wcp2018.0_sy35-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Pfister, Marc, Richard C. Brundage, Marc R. Gastonguay, Raymond Miller, Stacey J. Tannenbaum, and David Z. D'Argenio. "Defining the Future of Pharmacometrics: The American Society of Pharmacometrics." Journal of Clinical Pharmacology 50, S9 (September 2010): 158S. http://dx.doi.org/10.1177/0091270010377632.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Usman, Muhammad, Sitaram Khadka, Mohammad Saleem, Huma Rasheed, Bimal Kunwar, and Moshin Ali. "Pharmacometrics: A New Era of Pharmacotherapy and Drug Development in Low- and Middle-Income Countries." Advances in Pharmacological and Pharmaceutical Sciences 2023 (March 7, 2023): 1–10. http://dx.doi.org/10.1155/2023/3081422.

Full text

Abstract:

Pharmacotherapy, in many cases, is practiced at a suboptimal level of performance in low- and middle-income countries (LMICs) although stupendous amounts of data are available regularly. The process of drug development is time-consuming, costly, and is also associated with loads of hurdles related to the safety concerns of the compounds. This review was conducted with the objective to emphasize the role of pharmacometrics in pharmacotherapy and the drug development process in LMICs for rational drug therapy. Pharmacometrics is widely applied for the rational clinical pharmacokinetic (PK) practice through the population pharmacokinetic (popPK) modeling and physiologically based pharmacokinetic (PBPK) modeling approach. The scope of pharmacometrics practice is getting wider day by day with the untiring efforts of pharmacometricians. The basis for pharmacometrics analysis is the computer-based modeling and simulation of pharmacokinetics/pharmacodynamics (PK/PD) data supplemented by characterization of important aspects of drug safety and efficacy. Pharmacometrics can be considered an invaluable tool not only for new drug development with maximum safety and efficacy but also for dose optimization in clinical settings. Due to the convenience of using sparse and routine patient data, a significant advantage exists in this regard for LMICs which would otherwise lag behind in clinical trials.

APA, Harvard, Vancouver, ISO, and other styles

7

MORI, KAZUHIKO. "Medicament inspection and pharmacometrics." Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 29, no. 3 (1998): 565–66. http://dx.doi.org/10.3999/jscpt.29.565.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Manolis, Efthymios, and Ralf Herold. "Pharmacometrics for Regulatory Decision Making." Clinical Pharmacokinetics 50, no. 10 (October 2011): 625–26. http://dx.doi.org/10.2165/11594340-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

van der Graaf, Piet H. "CPT: Pharmacometrics and Systems Pharmacology." CPT: Pharmacometrics & Systems Pharmacology 1, no. 9 (September 2012): 8. http://dx.doi.org/10.1038/psp.2012.8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Waldman, S. A., and A. Terzic. "Advancing Pharmacometrics and Systems Pharmacology." Clinical Pharmacology & Therapeutics 92, no. 5 (November 2012): 535–37. http://dx.doi.org/10.1038/clpt.2012.151.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Pharmacometrics"

1

MELILLO, NICOLA. "Uncertainty and sensitivity analysis for mechanistic models in pharmacometrics." Doctoral thesis, Università degli studi di Pavia, 2020. http://hdl.handle.net/11571/1315928.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Björnsson, Marcus. "Pharmacometric Models in Anesthesia and Analgesia." Doctoral thesis, Uppsala universitet, Institutionen för farmaceutisk biovetenskap, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-205580.

Full text

Abstract:

Modeling is a valuable tool in drug development, to support decision making, improving study design, and aid in regulatory approval and labeling. This thesis describes the development of pharmacometric models for drugs used in anesthesia and analgesia. Models describing the effects on anesthetic depth, measured by the bispectral index (BIS), for a commonly used anesthetic, propofol, and for a novel anesthetic, AZD3043, were developed. The propofol model consisted of two effect-site compartments, and could describe the effects of propofol when the rate of infusion is changed during treatment. AZD3043 had a high clearance and a low volume of distribution, leading to a short half-life. The distribution to the effect site was fast, and together with the short plasma half-life leading to a fast onset and offset of effects. It was also shown that BIS after AZD3043 treatment is related to the probability of unconsciousness similar to propofol. In analgesia studies dropout due to lack of efficacy is common. This dropout is not at random and needs to be taken into consideration in order to avoid bias. A model was developed describing the PK, pain intensity and dropout hazard for placebo, naproxen and a novel analgesic compound, naproxcinod, after removal of a wisdom tooth. The model provides an opportunity to describe the effects of other doses or formulations. Visual predictive checks created by simultaneous simulations of PI and dropout provided a good way of assessing the goodness of fit when there is informative dropout. The performance of non-linear mixed effects models in the presence of informative dropout, with and without including models that describe such informative dropout was investigated by simulations and re-estimations. When a dropout model was not included there was in general more bias. The bias increased with decreasing number of observations per subject, increasing placebo effect and increasing dropout rate. Bias was relatively unaffected by the number of subjects in the study. The bias had, in general, little effect on simulations of the underlying efficacy score, but a dropout model would still be needed in order to make realistic simulations.

APA, Harvard, Vancouver, ISO, and other styles

3

Evbjer, Ellen. "Non-linear mixed effect models for the relationship between fasting plasma glucose and weight loss." Thesis, Uppsala universitet, Institutionen för farmaceutisk biovetenskap, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-205712.

Full text

Abstract:

Diabetes is one of the most common diseases in modern time. Its connection to overweight and obesity is well established, and diet and exercise are therefore important parameters in the treatment. A commonly used biomarker to diagnose and follow disease progression in diabetics is via measurements of fasting plasma glucose, FPG. In this study, the relationship between weight loss and FPG in overweight diabetics was studied. Competing hypothesis regarding the connection between weight loss and reduced FPG was investigated by using nonlinear mixed effects modeling based on data gathered from a meta-analysis by Anderson et al (1). The hypotheses suggested that either [1] weight effected FPG directly by an intermediate effector, or [2] both weight and FPG were affected by an unknown underlying mechanism. The intermediate effector was presumed to be insulin sensitivity and the underlying mechanism the blood concentration of free fatty acids. The data was gathered from 8 different studies, all examining the results of very low energy diets (330-909 kcal/day) in overweight type 2 diabetics. Frequent measurements of weight and FPG were provided in each study with a range of 91-321 mg/dl for baseline FPG and 93-118 kg for baseline weight. The summarized studies consisted of 13 arms with 6-62 subjects in each arm. Both hypotheses were modeled by using NONMEM 7.2. A stepwise effect was used for both weight and FPG. For hypothesis [1], an inhibitory effect affected the weight input which then affected the output for insulin sensitivity by a relative change in weight or the input for the insulin sensitivity by an absolute weight change. For hypothesis [2] the same inhibitory effect affected weight input and the input for insulin sensitivity. For both models the FPG drop was then proportional to the increase in insulin sensitivity. Hypothesis [2] had a significantly lower objective function value (OFV) than hypothesis [1] and had also better results from goodness of fit plots and VPCs. It was therefore concluded that hypothesis [2] indicated the more accurate explanation of the connection between FPG and weight loss. Moreover, a strong correlation between the caloric content of the diet and the rate of weight change was seen as a result of stepwise covariate modeling. An impact from baseline BMI on rate of change for insulin sensitivity was also seen.

APA, Harvard, Vancouver, ISO, and other styles

4

Hall, Adam J. "Structural and statistical aspects in joint modelling of artesunate pharmacometrics and malarial parasite lifecycle." Thesis, University of Warwick, 2015. http://wrap.warwick.ac.uk/81913/.

Full text

Abstract:

Malaria is a parasite with a complex lifecycle, and commonly used antimalarial agents from the artemisinin family have varied effectiveness over different stages of this lifecycle. The pharmacokinetic profile of the artemisinins is also strongly influenced by the parasite burden and lifecycle stage. This work introduces a new pharmacokinetic and pharmacodynamic model incorporating these interdependent drug and lifecycle features, for orally administered artesunate and its principal metabolite dihydroartemisinin. This model, like the underlying system whose features it attempts to capture, is quite complex and cannot be solved analytically like standard linear first-order compartmental models previously used for pharmacokinetic modelling of these drugs. Therefore, understanding, inference and validity are explored through use of the modern statistical technique of a Sequential Monte Carlo sampler. Structural, numerical and practical identifiability are important concepts for all models, the latter two especially so in this case as the model structure does not admit an algebraic structural identifiability analysis. Motivated by this, the above identifiability concepts are also investigated in connection with the Sequential Monte Carlo technique. Sequential Monte Carlo is demonstrated to be a useful tool for gaining insight into models whose structural identifiability is not known, just as it is also shown to have significant advantages in parameter inference over the classical approach. The coupled parasite lifecycle and artemisinin-derivative model is built in stages, starting with an in vitro submodel capturing the dynamics of uptake of artemisinins into parasitised and non-parasitised red blood cells. Next, the parasite lifecycle, or ‘ageing’ model, is introduced, which uses a new concept of shadow compartments to achieve its aims of describing ageing in continuous time and to exhibit sufficient control over the parasite population. Finally, these models are integrated together into the full coupled pharmacokinetic and pharmacodynamic model. More work is needed to fully assess the resultant model on clinical datasets, but the building blocks upon which it was constructed appear to fulfil their aims reasonably well.

APA, Harvard, Vancouver, ISO, and other styles

5

Hamberg, Anna-Karin. "Pharmacometric Models for Individualisation of Warfarin in Adults and Children." Doctoral thesis, Uppsala universitet, Klinisk farmakogenomik och osteoporos, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-197599.

Full text

Abstract:

Warfarin is one of the most widely used anticoagulants. Therapy is complicated by warfarin’s narrow therapeutic range and pronounced variability in individual dose requirements. Although warfarin therapy is uncommon in children, it is crucial for children with certain congenital or acquired heart diseases. Treatment in children is especially difficult due to the lack of i) a decision support tool for efficient and consistent dose adjustments, and ii) a flexible warfarin formulation for accurate and reproducible dosing. The overall aim of this thesis was to develop a PKPD-based pharmacometric model for warfarin that describes the dose-response relationship over time, and to identify important predictors that influence individual dose requirements both in adults and children. Special emphasis was placed on investigating the contribution of genetic factors to the observed variability. A clinically useful pharmacometric model for warfarin has been developed using NONMEM. The model has been successfully reformulated into a KPD-model that describes the relationship between warfarin dose and INR response, and that is applicable to both adults and children. From a clinical perspective, this is a very important change since it allows the use of information on dose and INR that is available routinely. The model incorporates both patient and clinical characteristics, such as age, weight, CYP2C9 and VKORC1 genotype, and baseline and target INR, for the prediction of an individualised starting dose. It also enables the use of information from previous doses and INR observations to further individualise the dose a posteriori using a Bayesian forecasting method. The NONMEM model has been transferred to a user-friendly, platform independent tool to aid use in clinical practice. The tool can be used for a priori and a posteriori individualisation of warfarin therapy in both adults and children. The tool should ensure consistent dose adjustment practices, and provide more efficient individualisation of warfarin dosing in all patients, irrespective of age, body weight, CYP2C9 or VKORC1 genotype, baseline or target INR. The expected outcome is improved warfarin therapy compared with empirical dosing, with patients achieving a therapeutic and stable INR faster and avoiding high INRs that increase the risk of bleeding.

APA, Harvard, Vancouver, ISO, and other styles

6

Ghadzi, Siti Maisharah Sheikh. "Pharmacometrics Modelling in Type 2 Diabetes Mellitus : Implications on Study Design and Diabetes Disease Progression." Doctoral thesis, Uppsala universitet, Institutionen för farmaceutisk biovetenskap, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-317040.

Full text

Abstract:

Pharmacometric modelling is widely used in many aspects related to type 2 diabetes mellitus (T2DM), for instance in the anti-diabetes drug development, and in quantifying the disease progression of T2DM. The aim of this thesis were to improve the design of early phase anti-diabetes drug development studies with the focus on the power to identify mechanism of drug action (MoA), and to characterize and quantify the progression from prediabetes to overt diabetes, both the natural progression and the progression with diet and exercise interventions, using pharmacometrics modelling. The appropriateness of a study design depends on the MoAs of the anti-hyperglycaemic drug. Depending on if the focus is power to identify drug effect or accuracy and precision of drug effect, the best design will be different. Using insulin measurements on top of glucose has increase the power to identify a correct drug effect, distinguish a correct MoA from the incorrect, and to identify a secondary MoA in most cases. The accuracy and precision of drug parameter estimates, however, was not affected by insulin. A natural diabetes disease progression model was successfully added in a previously developed model to describe parameter changes of glucose and insulin regulation among impaired glucose tolerance (IGT) subjects, with the quantification of the lifestyle intervention. In this model, the assessment of multiple short-term provocations was combined to predict the long-term disease progression, and offers apart from the assessment of the onset of T2DM also the framework for how to perform similar analysis. Another previously published model was further developed to characterize the weight change in driving the changes in glucose homeostasis in subjects with IGT. This model includes the complex relationship between dropout from study and weight and glucose changes. This thesis has provided a first written guidance in designing a study for pharmacometrics analysis when characterizing drug effects, for early phase anti-diabetes drug development. The characterisation of the progression from prediabetes to overt diabetes using pharmacometrics modelling was successfully performed. Both the natural progression and the progression with diet and exercise interventions were quantified in this thesis.

APA, Harvard, Vancouver, ISO, and other styles

7

LESTINI, GIULIA. "MODEL-BASED OPTIMAL DESIGN IN PHARMACOMETRICS USING ROBUST AND ADAPTIVE APPROACHES WITH APPLICATION IN ONCOLOGY." Doctoral thesis, Università degli studi di Pavia, 2016. http://hdl.handle.net/11571/1218159.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Quartino, Angelica L. "Pharmacometric Models for Improved Prediction of Myelosuppression and Treatment Response in Oncology." Doctoral thesis, Uppsala universitet, Institutionen för farmaceutisk biovetenskap, 2011. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-150431.

Full text

Abstract:

Chemotherapy plays an important role in the treatment of cancer. However, these drugs also cause death of non-malignant cells, resulting in severe side-effects. In addition, drug resistance may exist. Predictive tools for dose and drug selection are therefore warranted. In this thesis predictive pharmacometric models were developed for the main dose-limiting side-effect, neutropenia, and for treatment response following chemotherapy. Neutropenia is associated with a high risk for life-threatening infections and leads frequently to reduced dose delivery and thereby suboptimal treatment of the tumor. A better characterization of the dynamics of docetaxel induced neutropenia was obtained by simultaneous analysis of neutrophils and leukocytes. The fraction of neutrophils was shown to change over the time-course, hence leukocytes and neutrophil counts are not interchangeable biomarkers. Sometimes neutrophil count is reported as categorical severity of neutropenia (Grade 0-4). A method was developed that allowed analysis of these data closer to its true continuous nature. The main regulatory hormone of neutrophils is granulocyte colony stimulating factor (G-CSF). Although recombinant G-CSF is used as supportive therapy to prevent neutropenia, little is known of how the endogenous G-CSF concentrations vary in patients following chemotherapy. A prospective study was carried out and simultaneous analysis of endogenous G-CSF and neutrophils following chemotherapy enabled a more mechanistic model to be developed that also could verify the self-regulatory properties of the physiological system. Patient characteristics were investigated using a pharmacokinetic-myelosuppression model for docetaxel in patients with normal and impaired liver function. The model was a useful tool in evaluating different dosing strategies and a reduced dosing scheme was suggested in patients with poor liver function, thereby enabling docetaxel treatment in this patient population which has previously been excluded. Treatment of acute myeloid leukemia with daunorubicin and cytarabine is associated with drug resistance and high variability in pharmacokinetics, which was partly explained for daunorubicin by peripheral leukocyte count. An integrated model of the in vitro drug sensitivity and treatment response showed that in vitro drug sensitivity was predictive for treatment outcome in this patient population and may therefore be used for choice of drug. The developed pharmacometric models in this thesis may be useful in the optimization of treatments schedules for existing and new drugs as well as to assist in drug and dose selection to improve therapy in an individual patient. The models and methods presented may also facilitate pooled analysis of data and demonstrate principles which could be useful for the pharmacometric community.

APA, Harvard, Vancouver, ISO, and other styles

9

Røge, Rikke Meldgaard. "Pharmacometric Models of Glucose Homeostasis in Healthy Subjects and Diabetes Patients." Doctoral thesis, Uppsala universitet, Institutionen för farmaceutisk biovetenskap, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-274239.

Full text

Abstract:

Diabetes is a group of metabolic diseases characterized by hyperglycaemia resulting from defects in insulin secretion, insulin action, or both. Several models have been developed for describing the glucose-insulin system. Silber and Jauslin developed a semi-mechanistic integrated glucose insulin (IGI) model which simultaneously describe glucose and insulin profiles in either healthy subjects or type 2 diabetis mellitus (T2DM) patients. The model was developed for describing the basal system, i.e. when no drugs are present in the body. In this thesis the IGI model was extended to also include the effects of anti-diabetic drugs on glucose homeostasis. The model was extended to describe postprandial glucose and insulin excursions in T2DM patients treated with either biphasic insulin aspart or the GLP-1 receptor agonist liraglutide. These extensions make the model a useful tool in drug development as it can be used for elucidating the effects of new products as well as for clinical trial simulation. In this thesis several modelling tasks were also performed to get a more mechanistic description of the glucose-insulin system. A model was developed which describes the release of the incretin hormones glucosedependent insulinotropic polypeptide and glucagon-like peptide-1 following the ingestion of various glucose doses. The effects of these hormones on the beta cell function were incorporated in a model describing both the C-peptide and insulin concentrations in healthy subjects and T2DM patients during either an oral glucose tolerance test or an isoglycaemic intravenous glucose infusion. By including measurements of both C-peptide and insulin concentrations in the model it could also be used to characterize the hepatic extraction of insulin.

APA, Harvard, Vancouver, ISO, and other styles

10

CARRARA, LETIZIA. "Does the modelling strategy make the difference in pharmacometrics? Some examples in oncology and infectious diseases." Doctoral thesis, Università degli studi di Pavia, 2018. http://hdl.handle.net/11571/1214809.

Full text

Abstract:

The use of mathematical models to describe and predict the pharmacokinetics (PK), i.e., what the body does to the drug, and the phar- macodynamics (PD), i.e., what the drug does to the body, is fundamental across all the phases of the drug development process. Among the other things, these models allow to identify the most promising candidates during the preclinical studies, lead the dose selection for the First-In-Human (FIH) clinical trials, and enable to evaluate the effectiveness of a treatment and to simulate in silico different administration protocols. Nowadays, there are several modeling tools, each of which characterized by different features and specific applicability fields. There are models with a strong mechanistic base, such as the Physiologically Based Pharmacokinetic (PBPK) models, which integrate the information on organism anatomy and physiology with the physicochemical drug properties. There are also models with a poor mechanistic base, such as the standard pharmacokinetics/pharmacodynamics (PK/PD) models. Finally, there are models in which the pharmacokinetics is not explicitely modeled (K/PD). The scientific question of this thesis is whether an “optimal” modeling strategy exists for a given problem. In this perspective, the sentence of George Box: “All models are wrong, some are useful” should be kept in mind. Via some case studies, this thesis aimed to investigate two aspects: i) the suitability of a certain modeling strategy for a given problem in terms of model structure, available/required data, working hypotheses and the robustness of the results with respect to the assumptions made; ii) the dependency of conclusions from the adopted modeling approach. In Chapter 1, to set the scene, a brief introduction on both the drug discovery and development process and the importance of mathematical modeling throughout all the phases of this process was given. The features of the modeling strategies considered in this work to describe the pharmacokinetics and the pharmacodynamics were outlined in details. Subsequently, the scientific question underlying this work of thesis was discussed together with the methodology used to address it. In Chapter 2, the predictive performance of the Whole-Body (WB) PBPK models were investigated. To this aim, six "what-if" scenarios, in which data were added progressively into model development, starting from in vitro and animal experiments, up to human clinical trials, were created. Via these scenarios, the accuracy of the exposure predictions in dependence of the available data was evaluated. Ethambutol (EMB), one of the first-line antibiotics used for the treatment of pul- monary tuberculosis, was used as paradigm drug. When the physiological characterization of the subject with the dis- ease is not sufficient or not available, as in the oncology fields, less mechanistic approaches, i.e., the PK/PD and the K/PD models, were used to draw conclusions on the effectiveness of candidates. In Chapter 3 the most important models currently used for cancer drug discovery were surveyed. In Chapter 4 the dependency on the results from the specific mod- eling strategy was investigated using as a case study the predicted effect of two anticancer drug combination (Sunitinib and Irinotecan) in xenograft mice. In Chapter 5 in the attempt to be more mechanistic, additional details on drug behavior were added by considering drug concentration profiles not only in plasma but also into tumor tissue. In Chapter 6 overall conclusions were reported.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Pharmacometrics"

1

Ette, Ene I., and Paul J. Williams, eds. Pharmacometrics. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2007. http://dx.doi.org/10.1002/0470087978.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Schmidt, Stephan, and Hartmut Derendorf, eds. Applied Pharmacometrics. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1304-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Derendorf, Hartmut, and Stephan Schmidt. Applied Pharmacometrics. Springer, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Derendorf, Hartmut, and Stephan Schmidt. Applied Pharmacometrics. Springer, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Derendorf, Hartmut, and Stephan Schmidt. Applied Pharmacometrics. Springer, 2016.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

R, Laurence D., and A. L. Bacharach. Evaluation of Drug Activities: Pharmacometrics. Elsevier Science & Technology Books, 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

R, Laurence D., and A. L. Bacharach. Evaluation of Drug Activities: Pharmacometrics. Elsevier Science & Technology Books, 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ette, Ene I., and Paul J. Williams. Pharmacometrics: The Science of Quantitative Pharmacology. Wiley & Sons, Incorporated, John, 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Ette, Ene I., and Paul J. Williams. Pharmacometrics: The Science of Quantitative Pharmacology. Wiley & Sons, Incorporated, John, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Ette, Ene I., and Paul J. Williams. Pharmacometrics: The Science of Quantitative Pharmacology. Wiley & Sons, Incorporated, John, 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Pharmacometrics"

1

Hartford, Alan H., and Kenneth G. Kowalski. "Pharmacometrics." In Statistical Methods in Biomarker and Early Clinical Development, 321–48. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-31503-0_15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Brar, Satjit S., and Joga Gobburu. "Pharmacometrics." In Cancer Drug Discovery and Development, 173–92. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-9135-4_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Sy, Sherwin K. B., Xiaofeng Wang, and Hartmut Derendorf. "Introduction to Pharmacometrics and Quantitative Pharmacology with an Emphasis on Physiologically Based Pharmacokinetics." In Applied Pharmacometrics, 1–64. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1304-6_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Clancy, Cornelius Joseph. "Applied Antifungal Pharmacometrics: Fluconazole and Echinocandins in the Treatment of Candidemia and Invasive Candidiasis." In Applied Pharmacometrics, 297–323. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1304-6_10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Peloquin, Charles. "Pharmacometrics and Tuberculosis." In Applied Pharmacometrics, 325–48. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1304-6_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Kandala, Bhargava, and Günther Hochhaus. "Pharmacometrics in Pulmonary Diseases." In Applied Pharmacometrics, 349–82. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1304-6_12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Georgieva Kondic, Anna, Antonio Cabal, Ghassan N. Fayad, Khamir Mehta, Thomas Kerbusch, and Teun M. Post. "State-of-the-Art Pharmacometric Models in Osteoporosis." In Applied Pharmacometrics, 383–406. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1304-6_13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

de Lange, Elizabeth CM. "Pharmacometrics in Psychiatric Diseases." In Applied Pharmacometrics, 407–49. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1304-6_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Corrigan, Brian, Kaori Ito, James Rogers, Daniel Polhamus, Diane Stephenson, and Klaus Romero. "Clinical Trial Simulation in Alzheimer’s Disease." In Applied Pharmacometrics, 451–76. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1304-6_15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Menon, Sujatha, and Sriram Krishnaswami. "Pharmacometric Applications in Inflammation." In Applied Pharmacometrics, 477–98. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1304-6_16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pharmacometrics"

1

Katzper, Meyer. "Intrinsic dynamics and pharmacometric model discrimination." In the 27th conference. New York, New York, USA: ACM Press, 1995. http://dx.doi.org/10.1145/224401.224774.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Wahlquist, Ylva, Martin Morin, and Kristian Soltesz. "Pharmacometric covariate modeling using symbolic regression networks." In 2022 IEEE Conference on Control Technology and Applications (CCTA). IEEE, 2022. http://dx.doi.org/10.1109/ccta49430.2022.9966112.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Blau, Gary, and Seza Orcun. "A Bayesian pharmacometric approach for personalized medicine — A proof of concept study with simulated data." In 2009 Winter Simulation Conference - (WSC 2009). IEEE, 2009. http://dx.doi.org/10.1109/wsc.2009.5429214.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Sicard, Guillaume, Anne Rodallec, Florian Correard, Cristina Vaghi, Clair Poignard, Joseph Ciccolini, Sébastien Benzekry, Arnauld Sergé, and Raphaelle Fanciullino. "Abstract 6244: Turning poorly vascularized tumors into highly vascularized tumors with nanoparticles: Proof of concept and pharmacometric analysis." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-6244.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!